|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.02.26 - 22:03
|
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results (Business Wire)
|
|
|
Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year
Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million
Full Year 2025 worldwide revenue of $534.5 million – an increase of 14.9% year over year
Full Year 2025 net loss of $11.4 million and positive adjusted EBITDA of $61.8 million
2025 growth marked by expanding use of new products, including cryoSPHERE® MAX™ and AtriClip FLEX-Mini®, and the continued adoption of EnCompass® clamp
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2025 and full year 2025 financial results.
“Our 2025 performance reflects strong execution and continued momentum in our business. We delivered 15% revenue growth for the year and strengthened profitability while advancing key innovation ...
|
|
|
|
|
|
|
|
|
27.01.26 - 14:06
|
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
|
|
|
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026.
AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, February 17, 2026, to discuss its fourth quarter and full year 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricure.com/events-and-presentations/events.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriC...
|
|
|
|
|
12.01.26 - 16:30
|
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026 (Business Wire)
|
|
|
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance.
Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5 million, reflecting growth of approximately 13% over the fourth quarter of 2024 (12% on a constant currency basis). U.S. revenue is expected to be $114.3 million, reflecting growth of approximately 13%, and international revenue is expected to be $26.2 million, an increase of approximately 15% as reported (10% on a constant currency basis). Fourth quarter revenue was driven by continued strong growth in Pain Management, Open Ablation and Open AtriClip® devices.
Preliminary, unaudited revenue for full year 2025 is expected to be $534.5 million, reflecting growth of approximately 15%...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
